From the Sector

Amid the rapid spread of COVID-19 around the world, DyStar’s global operations continue to adapt to the development of the situation and to mitigate potential risks or impacts across the business. While the trajectory is unknown, DyStar is guided by recommendations from the World Health Organization and the local government authorities, to proactively address situations that could possibly affect our people and customers. This is to ensure that we have effective plans and standard procedures to minimize the disruption of our global operations.

Business Continuity Plan (BCP)
As a globally operating company, each of our operating sites, manufacturing plants, offices have a Business Continuity Plan (BCP) in place to sustain our operations and the supply chains we serve. The BCP, owned by our Business Continuity Management Team, provides clear guidance for all local operations, such as Administration, Customer Services, Finance, Logistics Services, Sales and Technical Support as well as Procurement, to enable all functions to continue operating effectively to serve our customers, distributors and agents.

Emergency Response Plan (ERP)
DyStar’s manufacturing sites are also installed with an Emergency Response Procedure to cover all emergency circumstances, including the COVID-19 pandemic disease. The goal of the emergency response procedure is to mitigate the impact of such events on people and the environment, ensuring operational readiness of the site during an emergency.

As the world adjusts to the impact of the COVID-19 pandemic, DyStar will continue to monitor the situation very closely and will provide updates that adapt to the changing situation. We remain committed to provide our customers with excellent service and to work closely with all our partners throughout this difficult period.

Brown Wrote to President Outlining Critical Steps White House can Take Now to Address Shortage of Personal Protective Equipment

 U.S. Sen. Sherrod Brown (D-OH) hosted a news conference call to discuss his plan for addressing the shortage of personal protective equipment (PPE) needed by healthcare workers on the frontline of keeping Americans healthy and safe during the coronavirus pandemic.

This weekend, Brown wrote to President Trump outlining several steps the Administration should take immediately to address the shortage and ramp up manufacturing of these critical medical supplies.

In his plan and in his letter to the President, Brown lists nine steps the Administration could take immediately, including:

1. Designate a government official who can serve as a point person responsible for coordination the acquisition and development of PPE, medical devices, and other supplies necessary to fight the coronavirus pandemic. 
2. Establish a PPE and medical device assessment and database to monitor the supply and anticipated needs for PPE, ventilators, diagnostic test kits, and other needed medical supplies to respond to the coronavirus pandemic. 
3. Publish a list of PPE, medical device, and general medical supply needs to respond to the coronavirus pandemic. 
4. Establish a hotline capable of handling significant call capacity that will provide U.S. producers centralized information about the results of the national assessment and the current need for PPE, devices, and other health care supplies. 
5. Provide immediate funding to manufacturers to purchase equipment, retool machinery, hire additional workers, and cover any other expenses needed to increase production of PPE and necessary medical devices and supplies.
6. Streamline contract and certification procedures to ensure production and delivery of materials are not delayed due to paperwork constraints.
7. Provide critical protections for workers who are making PPE, medical devices, and necessary supplies to receive a waiver from any shelter-in-place requirements to allow workers to volunteer to go to work in these critical industries. 
8. Provide purchase guarantees and delivery assistance of product to the communities and health care facilities that need the products most. 
9. Support companies that have the capacity to sterilize reusable equipment to alleviate the existing PPE shortage. 

In his plan, Brown also pointed out important legislative actions that will help ramp up production of these critical supplies, including expanding the strategic national stockpile authority, substantially increasing Defense Production Act funding and strengthening domestic preferences.

Textile innovator and specialty chemical producer Devan answers questions regarding anti-viral textile finish solutions following the growing spread of the COVID-19 outbreak.

Over the past few weeks, Devan has received a lot of questions regarding an antiviral solution for textiles against Sars-COV-2, the virus that causes COVID-19. “Not a big surprise since we put BI-OME AV forward 3 years ago. Testing has been done in cooperation with Institut Pasteur de Lille”, says Devan CEO Sven Ghyselinck. Devan studied enveloped viruses (e.g. H1N1, Corona-types, etc.) as well as naked viruses (e.g. Rotavirus). For both virus families, BI-OME AV showed strong to excellent activity in wet state.

In the first instance, the company wants to focus on professionals who need to stay working such as policemen, logistics workers, shop employees, day-care workers, … A common complication of respiratory viral disease can be a secondary bacterial infection. Professionals could be helped with either an anti-bacterial on their facemask to reduce the chance for these secondary bacterial infections, for better hygiene and less odor build-up. On workwear, a combination of a virus spread reducing and antibacterial solution could help as these garments are typically used during long hours, are non-disposable and most likely will be washed at home.

Devan has solutions which withstand washing while keeping its performance. BI-OME as a liquid product is EU BPR, Turkish BPR and US EPA registered. Depending on the rash region, commercialising treated articles be subject to additional local registration procedures.

Textile innovator and specialty chemical producer Devan answers questions regarding anti-viral textile finish solutions following the growing spread of the COVID-19 outbreak.

Devan studied enveloped viruses (e.g. H1N1, Corona-types etc.) as well as naked viruses (e.g. Rotavirus). For both virus families BI-OME AV showed strong activity in wet state.
In the first instance, the company wants to focus on professionals who need to stay working such as policemen, logistics workers, shop employees, day-care workers.

A common complication of respiratory viral disease can be a secondary bacterial infection. Professionals could be helped with either an anti-bacterial on their facemask to reduce the chance for these secondary bacterial infections, for better hygiene and less odour build-up. On workwear, a combination of a virus spread reducing and antibacterial solution could help as these garments are typically used during long hours, are non-disposable and most likely will be washed at home.
 

The corona pandemic has a significant impact on the global economy and thus also on the global automotive industry. The temporary plant closures at almost all customers in all regions will result in a revenue decline at Autoneum in the current year, the extent of which cannot yet be estimated.

In addition to the ongoing cost-saving programs, Autoneum has therefore decided on a comprehensive set of measures to further increase the flexibility of personnel and material expenses. This includes staff adjustments, e.g. by reducing the number of temporary employees in plants. In addition, short-time work at the Swiss sites, the Group’s headquarters in Winterthur and at the Sevelen plant (canton of Sankt Gallen), as well as short-time work in some other European countries and temporary closures of production facilities in various regions in line with those of customers are being implemented. With these measures, Autoneum is at the same time making its contribution to protecting the workforce, breaking chains of infection and containing the spread of this pandemic.

Despite the above-mentioned countermeasures and in light of the advancing spread of the coronavirus, Autoneum does not expect to achieve its targets for the business year 2020. Due to the considerable uncertainties regarding the course and duration of the pandemic, no updated outlook is provided for 2020 for the time being.

Textile and nonwoven associations issued a joint statement today urging federal, state and local governments to deem textile and nonwoven manufacturing facilities as “essential” when drafting “Shelter in Place” orders in response to the COVID-19 crisis.

Our associations recognize the serious challenges our elected officials, health administrators, and others are facing when issuing orders to protect communities across the country and we understand the necessity for leaders to enforce a ‘Shelter in Place” order or quarantine orders.

Our members make a broad range of inputs and finished products used in an array of personal protective equipment (PPE) and medical nonwoven/textile supplies, including surgical gowns, face masks, antibacterial wipes, lab coats, blood pressure cuffs, cotton swabs and hazmat suits. These items are vital to the government’s effort to ramp up emergency production of these critical supplies.

If workers who produce these goods are not granted an “essential” exemption from “Shelter in Place” and other quarantine orders to go to their manufacturing and distribution facilities, it will cause major disruptions in the availability of these goods. This will create significant hardship to healthcare providers and consumers across the country who depend on steady and stable supplies of these critical items.

We are asking the administration and state and local authorities to provide greater certainty and clarity for our companies and employees and ask for a clear exclusion of our manufacturing operations from “Shelter in Place” orders as the textile and nonwoven products that we make in the U.S. play an essential role in mitigating the shortages of critical supplies. Such a designation will help us avoid disruptions of vital goods and services during this challenging time.

HeiQ, winner of the Swiss Technology Award and Swiss Environmental Award, launches HeiQ Viroblock NPJ03, an antiviral and antimicrobial textile treatment that is tested effective against coronavirus.

Since its inception 15 years ago, HeiQ has forged a solid innovation track record helping brands improve textile products. Catalyzed to action by the global fight against Coronavirus, HeiQ launches HeiQ Viroblock NPJ03, an antiviral and antimicrobial textile treatment which is proven effective against human coronavirus (229E) in face mask testing, significantly enhancing the antiviral log reduction from 2.90 of untreated face masks to 4.48, over 99.99% reduction of virus infectivity. (Remarks: a log reduction of 2 is equivalent to 100 times the effectiveness).

Chinese protective masks producer Suzhou Bolisi is the lead adopter of HeiQ Viroblock NPJ03. Treated masks will be available on the market as early as this April. American legwear manufacturer Kayser-Roth is planning to add the technology to their new product, Ghluv hands protector, while Lufeng from China is evaluating the technology on other types of fabric used for garments.

HeiQ Viroblock NPJ03 is a unique combination of vesicle and silver technologies designed to inhibit the growth and persistence of bacteria and viruses. The HeiQ vesicle technology targets lipid- enveloped viruses, such as coronavirus, providing rapid virus deactivation, while the HeiQ silver technology inhibits the replication of both bacteria and viruses. HeiQ Viroblock NPJ03 can be applied to a wide spectrum of textile surfaces including face masks, air filters, medical gowns, curtains, drapes and more. HeiQ also has a range of highly wash-durable antimicrobial and odor control textile technologies, called HeiQ Pure, combining silver-based and bio-based materials for all fabric types.

Rejects Importer Attempts to Remove China 301 Tariffs on Finished Products

The National Council of Textile Organizations (NCTO), representing the full spectrum U.S. textiles from fiber through finished sewn products, issued a statement today welcoming the Trump administration’s proposals on an economic stimulus package to gird the economy against the impact of the coronavirus outbreak, but the organization urged officials to reject any attempts by importers to remove China 301 tariffs on finished products as part of any relief package.

As part of a Phase One deal with China, the administration reduced duties on finished apparel and textile products implemented on Sept.1 from 15 percent to 7.5 percent. Finished apparel, home furnishings and other made-up textile goods equate to 93.5 percent of U.S. imports from China in the sector; while fiber, yarn, and fabric imports from China only represent 6.5 percent, according to government data.

NCTO is a Washington, DC-based trade association that represents domestic textile manufacturers, including artificial and synthetic filament and fiber producers.

• U.S. employment in the textile supply chain was 594,147 in 2018.

• The value of shipments for U.S. textiles and apparel was $76.8 billion in 2018.

• U.S. exports of fiber, textiles and apparel were $30.1 billion in 2018.

• Capital expenditures for textile and apparel production totaled $2.0 billion in 2017, the last year for which data is available.